NCT02119156 - Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2014

Primary Completion Date

December 14, 2018

Study Completion Date

December 14, 2018

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Belimumab

Monthly intravenous infusions dosed as 10 mg/kg body weight

Trial Locations (20)

11030

GSK Investigational Site, Manhasset

75246

GSK Investigational Site, Dallas

90048

GSK Investigational Site, Los Angeles

100032

GSK Investigational Site, Beijing

100044

GSK Investigational Site, Beijing

215006

GSK Investigational Site, Suzhou

230001

GSK Investigational Site, Hefei

310009

GSK Investigational Site, Hangzhou

275-8580

GSK Investigational Site, Chiba

791-0295

GSK Investigational Site, Ehime

060-8604

GSK Investigational Site, Hokkaido

980-8574

GSK Investigational Site, Miyagi

857-1195

GSK Investigational Site, Nagasaki

104-8560

GSK Investigational Site, Tokyo

162-8655

GSK Investigational Site, Tokyo

700-721

GSK Investigational Site, Daegu

110-744

GSK Investigational Site, Seoul

133-792

GSK Investigational Site, Seoul

Unknown

GSK Investigational Site, Seoul

443-721

GSK Investigational Site, Suwon, Kyonggi-do